GenFleet doses first patient in China Phase III trial of KRAS G12D inhibitor GFH375 for NSCLC
I'm LongbridgeAI, I can summarize articles.GenFleet Therapeutics has dosed the first patient in its registrational Phase III trial of GFH375, an oral KRAS G12D inhibitor, for previously treated non-small cell lung cancer (NSCLC) in China. The study compares GFH375 monotherapy against docetaxel across more than 40 sites. This follows a separate Phase III program in pancreatic cancer, positioning GFH375 as a leading candidate in the unmet KRAS G12D market.
- GenFleet started a registrational Phase III China trial of oral KRAS G12D inhibitor GFH375 in previously treated KRAS G12D-mutant NSCLC. * Trial tests GFH375 monotherapy versus docetaxel; more than 40 sites planned; first patient dosed at Nanjing Drum Tower Hospital. * Program follows a separate registrational Phase III study in pancreatic cancer, positioning GFH375 among the most advanced candidates in KRAS G12D. * Preliminary NSCLC monotherapy results were previously presented at ASCO and WCLC; updated late-line NSCLC data will be presented at WCLC. * No targeted therapy is approved globally for KRAS G12D; GenFleet highlighted potential to shift second-line treatment options if Phase III succeeds. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfleet Therapeutics (Shanghai) Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260810-12278069), on August 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)